Novartis AG vs Eli Lilly & Co.
NVS vs LLY — side-by-side comparison from reported financials. NVS leads 2, LLY leads 9 of 11 comparable metrics.
Novartis AG
NVS · Healthcare
$143.75+0.45%Solid
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | NVS | LLY |
|---|---|---|
| Price | $143.75 | $1 177.20 |
| Market cap | $273B | $1.05T |
| Revenue (TTM) | $56.7B | $79.7B |
| Revenue growth | +9.1% | +31.7% |
| Net margin | 24.7% | 33.5% |
| Free cash flow | $16.8B | $18.2B |
| Net cash (debt) | ($41.4B) | ($35.2B) |
| 1-year price return | +9.7% | +37.6% |
| P/E | 20.3 | 41.6 |
| P/E vs own history (cheap-side %) | 46% | 88% |
| Dividend yield | 3.49% | 0.52% |
| Return on equity | 30% | 93% |
| Altman Z-score | 3.50 | 7.10 |
| CV checks passed | 11 of 11 | 11 of 11 |
| Employees | 75,267 | 50,000 |
Full résumé-style profiles: NVS CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.